Xeris Biopharma HoldingsXERS -3.30%71 Gross Margin % is 87.28% as of Mar. 2026, which is 7% above its 10-year median of 81.86. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.19 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 943 Drug Manufacturers companies, Xeris Biopharma Holdings ranks better than 96.18% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Xeris Biopharma Holdings had a gross margin of 87.28% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Xeris Biopharma Holdings Gross Margin % Related Terms
Xeris Biopharma Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XERS vs PAHC, PRGO, ALVO: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Xeris Biopharma Holdings (XERS) has a Gross Margin % of 87.28% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Xeris Biopharma Holdings and its competitors. This is near median its historical median of 81.86. Over the past decade, Xeris Biopharma Holdings' Gross Margin % has ranged from 41.11 to 99.74. According to the industry distribution chart, Xeris Biopharma Holdings ranks #36 out of 943 companies in the Drug Manufacturers industry, placing it in the top 3.8%.
Is Xeris Biopharma Holdings' Gross Margin % too high?
Xeris Biopharma Holdings' current Gross Margin % of 87.28% is near median its 10-year median of 81.86. Over the past 10 years, this metric has ranged from a low of 41.11 to a high of 99.74. The Drug Manufacturers industry median Gross Margin % is 48.54. Xeris Biopharma Holdings' value of 87.28% is 79.8% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #36 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Gross Margin % compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #36 out of 943 companies for Gross Margin %. This places Xeris Biopharma Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Xeris Biopharma Holdings' value of 87.28% is 79.8% above this benchmark. Historically, Xeris Biopharma Holdings' own Gross Margin % has ranged from 41.11 to 99.74 over the past decade. While the company's 10-year median is 81.86 vs. the industry median of 48.54, Xeris Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Gross Margin % of 87.28% is 79.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Gross Margin % is 87.28%, which is near median its own 10-year median of 81.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.19, compared to a current price of $8.35 — trading 60.9% above its estimated fair value. The current Gross Margin % is 87.28%, which is near median its 10-year median of 81.86 and 79.8% above the Drug Manufacturers industry median of 48.54. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Gross Margin % is 87.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for XERS:
Gross Margin %: 87.28% (near median its 10-year median of 81.86)
GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
Industry Position: 79.8% above the Drug Manufacturers median (#36 of 943)
No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score
Get the complete analysis for XERS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XERS has been successfully added to your 
